Vivakor, Inc. Announces Stock Dividend
November 17 2009 - 8:01AM
PR Newswire (US)
CORALVILLE, Iowa, Nov. 17 /PRNewswire-FirstCall/ -- Vivakor, Inc.
(OTC Bulletin Board: VIVK) today announced that its Board of
Directors approved a dividend of shares of common stock of
HealthAmerica, Inc., a Nevada corporation of which Vivakor owns
approximately 84% of the outstanding common stock. Each Vivakor
shareholder will be entitled to receive one share of HealthAmerica
common stock for each share of Vivakor common stock beneficially
owned on the record date. The record date for the distribution is
expected to be December 1, 2009, subject to review and approval of
FINRA, and the distribution date is expected to be December 9,
2009. After the dividend distribution, Vivakor will continue to own
approximately 62% of the outstanding common stock of HealthAmerica.
Vivakor shareholders will not be required to take any action to
receive the HealthAmerica common shares on the distribution date.
Vivakor Chairman Matt Nicosia commented on the Board's decision,
"HealthAmerica is a terrific company and we feel that, with its
technology and our innovation team's collaboration, we will see
substantial revenues for HealthAmerica in the near future. By
committing to this dividend, we demonstrate not only our belief in
HealthAmerica and its technology, but we also affirm to our
shareholders our confidence in our own strategy and the long term
and short term value of their investment in Vivakor." About
Vivakor, Inc. Vivakor(TM) is a biomedical/biotechnology company
with transdisciplinary research that develops and acquires products
in the fields of molecular medicine, electro-optics, biological
handling and natural and formulary compounds, that extend or
improve life. More information can be found about Vivakor at
http://www.vivakor.com/. About HealthAmerica, Inc. HealthAmerica is
developing a patented, FDA 510(k) cleared, technology
(VIVASlices(TM)) that is expected to enhance the resolution of
images resulting from MRI. The underlying algorithm may also be
useful in determining blood flow velocity measures in imaged
tissues, which would be valuable in accessing areas of blood flow
constriction from plaques or other hematologic deposits. This
information could help physicians better diagnose, predict and
assess stroke and related diseases involving blood flow
obstruction. At the end of 2000, there were approximately 9,500 MRI
(magnetic resonance imaging) systems installed worldwide. While
changes in medical reimbursements have slowed the sale of new
machines, there is an increased demand for improved efficiency
(i.e. accelerated patient throughput) from current systems.
Additionally, intense competition between various medical
facilities and the rapid distribution of new advances in imaging
(such as MR angiographies, which allow evaluation of blood vessels
without any invasive procedure) puts additional pressure on MRI
because increased image quality requires additional time. Thus
there is a huge need for an application like VIVASlices that can
improve both throughput and image quality. VIVASlices consists of a
combination of hardware and software and is being designed to
improve the quality and efficiency of magnetic resonance image
systems. At the core of the system is a totally novel method of
reconstructing the MR information obtained by the machine (the raw
data). Contrary to the Fourier reconstruction technique, used by
all manufacturers on all machines, regardless of the field strength
(as well as on numerous CT scanners), VIVASlices will use a unique
algorithm, exchange analytic computation technique (EXACT), which
decouples the size of the raw data from the image matrix size and
overcomes many of the inherent limitations of the Fourier
transformations. The technology will allow tremendous flexibility
once the MRI data has been acquired; it will be possible using
VIVASlices to obtain sharply magnified images, up to ten times the
original magnification, without creating pixel artifacts inherent
to the optical zoom provided by all manufacturers. The major
benefits of VIVASlices technology are: -- Increased information
extraction -- Helps with the elimination of artifacts -- Improves
the radiologists productivity -- Reduces patient re-scan and call
back -- Reduces patient scan time -- Reduces film costs By
eliminating the limitations of FFT-based k-space processing,
VIVASlices will process raw (k-space) MR data into superior-quality
images for any patient study without filtering, blurring, data
padding or interpolation. Further it will produce superb,
high-resolution MR angiograms. VIVASlices(TM) will work on low, mid
and high field magnets and is very easy to use. FORWARD-LOOKING
STATEMENTS This press release may contain forward-looking
statements, including, but not limited to, statements regarding
Vivakor's and HealthAmerica's products. Forward-looking statements
may be identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," or "continue" and variations
or similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks and uncertainties discussed in Vivakor's filings with the
Securities and Exchange Commission, which factors are incorporated
herein by reference. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. Vivakor
undertakes no obligation to update any of these forward-looking
statements to reflect events or circumstances after the date of
this press release or to reflect actual outcomes. Contact: Vivakor,
Inc. Matt Nicosia, 319-625-2172 DATASOURCE: Vivakor, Inc. CONTACT:
Matt Nicosia of Vivakor, Inc., +1-319-625-2172, Web Site:
http://www.vivakor.com/
Copyright